Safety and tolerability of caspofungin acetate in the treatment of fungal infections.

@article{Sable2002SafetyAT,
  title={Safety and tolerability of caspofungin acetate in the treatment of fungal infections.},
  author={C A Sable and B-Y. Nguyen and Jeffery A Chodakewitz and Mark J Dinubile},
  journal={Transplant infectious disease : an official journal of the Transplantation Society},
  year={2002},
  volume={4 1},
  pages={25-30}
}
Caspofungin acetate is the first member of the novel echinocandin class of antifungal drugs to be marketed in the United States. It has recently been approved for use in patients with invasive aspergillosis who are refractory to or intolerant of conventional therapy. Accordingly, its safety profile is particularly important to review. The safety and tolerability of caspofungin have been examined in 623 persons, including 295 patients who received >/= 50 mg/day for at least one week in clinical… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 42 extracted citations

Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society • 2016
View 2 Excerpts

Invasive fungal infections in solid organ transplant recipients.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases • 2014
View 1 Excerpt

Similar Papers

Loading similar papers…